Allscripts' e-prescribing solution is an Electronic Health Record (EHR) software that automates the process of writing prescriptions. EHR system enables physicians to send prescriptions directly to a pharmacy by e-mail. It has been proven that the effective use of EHR systems reduces medical errors, enhances clinical quality and leads to better patient outcomes by accessing patient records in real time.

The U.S. government is increasingly emphasizing the use of EHR systems these days, as evident from the Medicare Improvements for Patients and Providers Act of 2008. For the first time ever, the Act provides financial incentives to physicians who adopt e-prescribing. This requires adoption by 2011 and delays any reduction in fees for treating Medicare patients.

We believe that the new agreement will boost Allscripts' top-line by expanding its client base. Libertyville, IL-based Allscripts Healthcare Solutions Inc. is a leading provider of clinical software and information solutions meant for physicians. In Oct 2008, the company merged with Misys Plc, a global applications software and services company, to form Allscripts−Misys Healthcare Solutions Inc.

Allscripts faces strong competition from Cerner Corp. (CERN), Merge Healthcare Inc. (MRGE), Quality Systems Inc. (QSII) and MedAssets Inc. (MDAS).

Presently, we are "Neutral" on Allscripts.

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).

These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.

Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760

Zacks #1 Ranked Health Care Funds

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

About Zacks Mutual Fund Rank

The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.

To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.

To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Jim Giaquinto 
Company: Zacks.com 
Phone: 312-265-9149 
Email: pr@zacks.com 
Visit: www.zacks.com

Below we will share with you 5 top rated healthcare funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect the fund to outperform its peers in the future. To view the Zacks Rank and past performance of all health funds, then click here.

Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.

The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.

ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.

The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.

Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.

This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.

Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.

Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.

Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.

As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.

To view the Zacks Rank and past performance of all health funds, then click here.

About Zacks Mutual Fund Rank

By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Learn more about the Zacks Mutual Fund Rank at http://www.zacks.com/funds/mutualfund/.

The companies have opted for a cash tender offer for all of AMICAS' outstanding common stock. The offer is expected to commence in about two weeks. Any untendered shares of AMICAS common stock will be converted into the right to receive the same at $6.05 per share in cash.

Merge has already obtained $200 million of bridge financing from Morgan Stanley and $40 million of equity purchase commitments from private investors to fund the acquisition.

The successful acquisition of AMICAS will enable Merge to acquire one of its main competitors and widen its customer base. This will, in turn, expand the company's top-line.

Merge is a healthcare software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow, and intelligently managing and distributing diagnostic images and information throughout the healthcare enterprise.

Merge was paralyzed by several issues in the past like a dwindling cash balance, management turnover, accounting miscues and litigations. The real turnaround started from the second quarter of 2008 when the company received the much-needed cash infusion of $20 million from Merrick RIS, LLC in May 2008.

Presently, we have an Underperform recommendation for Merge.

The Dow average managed to erase its losses for the second time in as many days, but failed to hold on to those gains and ended the session marginally lower.  The tech-heavy Nasdaq and the broader S&P 500 index ended the day little changed.  On the New York Stock Exchange, advancing shares beat those that declined in price by an eight-to-seven margin on volume of 950 million shares. 

Healthcare stocks also suffered after Medivation Inc. (NASDAQ:MDVN) said it experimental Alzheimer’s disease drug Dimebon failed to meet primary and secondary goals in a late-stage clinical study.  Medivation is co-developing the drug with Pfizer (NYSE:PFE).  

Meanwhile, Greece’s announcement of fiscal austerity measures diminished fears of an impending financial crisis in the euro zone. Nevertheless, traders chose to remain on the sidelines ahead of the Friday’s monthly jobs report and reacted mildly to Fed’s announcement that economic activity picked up modestly in 9 of the 12 Fed districts.

Risk-aversion pushed traders towards commodities, sending crude prices up 1.5% to top $80 at $80.87 per barrel; gold advanced $5.90 to close at $1,143.30; copper prices rose 2.4%; and the broad-based, DJ-UBS commodities index climbed 1.1% to 135.857.  Meanwhile, safe-haven US Treasuries fell in price, with the 10-year off 3/32 as its yield jumped to 3.621%.  The US dollar dropped 0.4% to 80.00 against a basket of currencies as hope grew Greece’s fiscal austerity measures would show desired results, and labor market showed signs of stabilization.

Action was evenly split among the ten S&P500 industry sectors, with basic materials (+0.7%), consumer goods (+0.4%), oil and gas (+0.3%), industrials (+0.3%), and technology stocks (+0.01%) leading on the upside.  Health care and financial stocks closed down 0.3% and 0.1%, respectively, with consumer services off 0.2%, and telecom and utilities down 0.1%.

A number of retailers are scheduled to report their monthly sales numbers.  Although the numbers are expected to reflect dismal weather conditions, pickups in grocery sales and online shopping would somewhat balance the equations. Analysts anticipate a 2.9% gain. Productivity and costs for the fourth quarter is also due, with numbers expected unchanged.

Among the few corporate results expected, Anheuser-Busch (NYSE:BUD) and Marvell Tech (NASDAQ:MRVL) are slated to report. Fed speakers today include St. Louis Fed President Bullard and Chicago Fed President Evans.

The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors.

In the present scenario, investor sentiment in healthcare continues to be driven by decisions in the Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in the Congress, healthcare policy changes remain an important indicator to investing in the sector. The Health Bill intends to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income.

President Obama has made a last-ditch effort to revive the stalled U.S. healthcare overhaul with a plan to make insurance more affordable and to bolster government authority to regulate premium hikes. The plan, which aims to break an impasse in the U.S. Congress, intends to provide coverage to millions of uninsured Americans and set up federal monitoring of private insurers' rate increases. The President’s proposal comes following months of debate on reform in the Senate and House of Representatives over their respective legislation.

As per the plan, health insurers would have to spend at least 80% of their premiums on medical care, a move that could result in penalties for 16% of health insurers. Furthermore, the proposed plan intends to penalize health insurers who spend more than 20% of premiums on operational costs, such as salaries and marketing.

Exorbitant rate hikes and profit margins became the subject of public debate after WellPoint Inc. (WLP) issued letters to the policyholders of its subsidiary Anthem Blue Cross in California, warning them of steep rate hikes.

Recently, the U.S. House of Representatives voted to strip health insurance companies of a 65-year-old antitrust exemption. The 406 to 19 vote aims to repeal an antitrust exemption that has meant that states take the lead in enforcing antitrust law for health insurers.

OPPORTUNITIES

We are positive on Health Net Inc. (HNT) on which we have an Outperform rating. While we remain concerned about the decline in membership, we believe a gradual improvement of the US economy should improve its membership status. Moreover, a strong balance sheet should enable it to tackle the current scenario.

Health technology holds the promise of improved operating efficiencies for many parts of the healthcare industry, hospitals included. However, in the short term those that stand to benefit the most from the stimulus are companies whose business models are based on information technology platforms.

One such company is BioScrip, Inc. (BIOS) on which we are positive despite its neutral rating. BioScrip is a specialty pharmacy services provider and pharmacy benefit manager. The company operates two interrelated business segments, namely: Specialty Services, which consists of specialty pharmacy distribution and clinical management services; and Traditional Pharmacy Services (previously referred to as PBM Services), which consists of pharmacy benefit management and traditional mail services.

The company’s diversified product mix across several key disease areas including immunology, multiple sclerosis and oncology should drive growth. The oral oncology business continues to show robust growth and should remain a strong part of the company’s business. We are pleased to see that the company is working on expanding its national reach and local presence and is adding infusion capacity in markets which have a large number of members.

We believe BioScrip is well-positioned to benefit from future healthcare reform initiatives like broader insurance coverage, the approval of a pathway for bio-similars and incentives supporting the utilization of information technology systems. The implementation of these initiatives is in line with the company’s strategy and should bode well for its future.

Another company on which we are positive -- despite its current Neutral recommendation -- is ZOLL Medical Corporation (ZOLL). We are pleased with the company’s wide range of products and significant international presence. The company has made multiple acquisitions in the past, which have aided growth and is looking out for more such opportunities.

The company is a leading player in the global market for external defibrillators, which is worth over $1 billion annually. ZOLL Medical has innovated a wide range of product features that have become the standard of care in the external defibrillator industry. The company is expanding its offerings to sustain growth.

WEAKNESSES

We recommend avoiding names like Molina Healthcare (MOH), on which we have an Underperform rating because of its declining profitability attributable to increasing medical costs due to the H1N1 influenza pandemic and costs associated with recently enrolled members. The impact of the pandemic is significant and has the potential to worsen in the coming quarters, affecting its profitability further.

Another company on which we are negative and have an Underperform rating is Aetna Inc. (AET), a diversified health care benefits company. Recently, the company delivered disappointing fourth quarter 2009 results. Aetna reported fourth quarter operating earnings per share (EPS) of 40 cents, missing the Zacks Consensus Estimate of 42 cents and was 58% lower than 96 cents reported in the year-ago quarter.

The primary reason for the decline was lower commercial underwriting margin, lower operating earnings in the Group Insurance business and an increase in pension expenses, partially offset by the lower number of outstanding shares. For full year 2009, operating EPS came in at $2.75, a 30% decline from last year.

The company is witnessing several headwinds such as rising unemployment, uncertainty related to healthcare reform and increasing cost pressure among others. Furthermore, intense competition facing the company is also a concern. Aetna competes with local and regional healthcare benefit plans in addition to large commercial health benefit insurance companies such as United Health (UNH) and WellPoint, among others, and Blue Cross/Blue Shield plans.

The outlook provided by the company for 2010 is not very bright either. Aetna projects full-year 2010 operating EPS in the range of $2.55 − $2.65, way below the Zacks Consensus Estimate of $2.86. Consequently, we advise investors to avoid the stock.

In general, health insurers are facing a drop in enrollment in their commercial segment. Insurers like Aetna Inc., Cigna Corp. (CI) and Humana Inc. (HUM) have resorted to job cuts to tide over difficult times.

Bayer’s core earnings per share (EPS) came in at €0.90 (approx $1.23) compared to €0.71 (approx. $0.96) in the year-ago period. The Zacks Consensus Estimate during the reported quarter was $1.14. For 2009, the company recorded a 12.7% decline in core EPS to €3.64 (approx $4.96). 2009 earnings were lower due to €766 million of charges associated with certain restructuring measures and litigation. However, the company does not expect to incur these charges in 2010.

The three major segments: Healthcare, CropScience and MaterialScience accounted for 53%, 18% and 26%, respectively of total revenues during the reported quarter. Healthcare and CropScience segment revenues improved by 0.6% and 3.4%, respectively.

The Healthcare segment recorded revenues of €4.16 billion compared to €4.14 billion in the corresponding period last year. Both the divisions of Healthcare – pharmaceuticals and consumer health were almost unchanged from the previous quarter. During 2009, this segment generated a 3.8% rise in revenues to $15.98 billion.

Bayer’s primary market, Europe – accounting for 40% of its Healthcare revenues in 2009 remained almost unchanged compared to 2008. The other markets of North America, Asia-Pacific and Latin America/Africa/Middle East grew 2.7%, 17.5% and 4.2%, respectively.

Revenues from CropScience increased 3.4% to €1.4 billion during the quarter on higher volume although prices came down by 3.6%. New product sales increased 5.2% to €426 million representing 30% of the total portfolio.

Revenues from Crop Protection (division of CropScience) increased 4.7% to €1.17 billion. However, sales of Environmental Science/BioScience dropped 3.1% to €221 million.

Material Science recorded revenues of €2.02 billion, down 1.9% from the year-ago period due to a 17.6% decline in price of the products, but were offset by higher volume.

Although gross cash flow for 2009 declined 12% to €4.6 billion, net cash flow rose 49% to €5.4 billion because of improvements in working capital. The company reduced its net debt to €9.7 billion at the end of the year from €14.2 billion at the end of 2008. However, in 2009, Bayer’s earnings before interest, tax, depreciation and amortization (EBITDA) before special items declined 6.6% to €6.47 billion against its guidance of a 5% fall.

Bayer expects to post more than 5% currency and portfolio adjusted sales growth for 2010 with EBITDA before special items rising towards €7 billion. Core EPS is expected to improve by 10%. We believe growth in the Healthcare business is particularly important for Bayer as it has shifted focus to this area, which accounts for more than 50% of total revenues. We expect the MaterialScience business to pick up in 2010 when the world economy recovers from the current recession.
 

The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors.

In the present scenario, investor sentiment in healthcare continues to be driven by decisions in the Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in the Congress, healthcare policy changes remain an important indicator to investing in the sector. The Health Bill intends to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income.

President Obama has made a last-ditch effort to revive the stalled U.S. healthcare overhaul with a plan to make insurance more affordable and to bolster government authority to regulate premium hikes. The plan, which aims to break an impasse in the U.S. Congress, intends to provide coverage to millions of uninsured Americans and set up federal monitoring of private insurers' rate increases. The President’s proposal comes following months of debate on reform in the Senate and House of Representatives over their respective legislation.

As per the plan, health insurers would have to spend at least 80% of their premiums on medical care, a move that could result in penalties for 16% of health insurers. Furthermore, the proposed plan intends to penalize health insurers who spend more than 20% of premiums on operational costs, such as salaries and marketing.

Exorbitant rate hikes and profit margins became the subject of public debate after WellPoint Inc. (WLP) issued letters to the policyholders of its subsidiary Anthem Blue Cross in California, warning them of steep rate hikes.

Recently, the U.S. House of Representatives voted to strip health insurance companies of a 65-year-old antitrust exemption. The 406 to 19 vote aims to repeal an antitrust exemption that has meant that states take the lead in enforcing antitrust law for health insurers.

OPPORTUNITIES

We are positive on Health Net Inc. (HNT) on which we have an Outperform rating. While we remain concerned about the decline in membership, we believe a gradual improvement of the US economy should improve its membership status. Moreover, a strong balance sheet should enable it to tackle the current scenario.

Health technology holds the promise of improved operating efficiencies for many parts of the healthcare industry, hospitals included. However, in the short term those that stand to benefit the most from the stimulus are companies whose business models are based on information technology platforms.

One such company is BioScrip, Inc. (BIOS) on which we are positive despite its neutral rating. BioScrip is a specialty pharmacy services provider and pharmacy benefit manager. The company operates two interrelated business segments, namely: Specialty Services, which consists of specialty pharmacy distribution and clinical management services; and Traditional Pharmacy Services (previously referred to as PBM Services), which consists of pharmacy benefit management and traditional mail services.

The company’s diversified product mix across several key disease areas including immunology, multiple sclerosis and oncology should drive growth. The oral oncology business continues to show robust growth and should remain a strong part of the company’s business. We are pleased to see that the company is working on expanding its national reach and local presence and is adding infusion capacity in markets which have a large number of members.

We believe BioScrip is well-positioned to benefit from future healthcare reform initiatives like broader insurance coverage, the approval of a pathway for bio-similars and incentives supporting the utilization of information technology systems. The implementation of these initiatives is in line with the company’s strategy and should bode well for its future.

Another company on which we are positive -- despite its current Neutral recommendation -- is ZOLL Medical Corporation (ZOLL). We are pleased with the company’s wide range of products and significant international presence. The company has made multiple acquisitions in the past, which have aided growth and is looking out for more such opportunities.

The company is a leading player in the global market for external defibrillators, which is worth over $1 billion annually. ZOLL Medical has innovated a wide range of product features that have become the standard of care in the external defibrillator industry. The company is expanding its offerings to sustain growth.

WEAKNESSES

We recommend avoiding names like Molina Healthcare (MOH), on which we have an Underperform rating because of its declining profitability attributable to increasing medical costs due to the H1N1 influenza pandemic and costs associated with recently enrolled members. The impact of the pandemic is significant and has the potential to worsen in the coming quarters, affecting its profitability further.

Another company on which we are negative and have an Underperform rating is Aetna Inc. (AET), a diversified health care benefits company. Recently, the company delivered disappointing fourth quarter 2009 results. Aetna reported fourth quarter operating earnings per share (EPS) of 40 cents, missing the Zacks Consensus Estimate of 42 cents and was 58% lower than 96 cents reported in the year-ago quarter.

The primary reason for the decline was lower commercial underwriting margin, lower operating earnings in the Group Insurance business and an increase in pension expenses, partially offset by the lower number of outstanding shares. For full year 2009, operating EPS came in at $2.75, a 30% decline from last year.

The company is witnessing several headwinds such as rising unemployment, uncertainty related to healthcare reform and increasing cost pressure among others. Furthermore, intense competition facing the company is also a concern. Aetna competes with local and regional healthcare benefit plans in addition to large commercial health benefit insurance companies such as United Health (UNH) and WellPoint, among others, and Blue Cross/Blue Shield plans.

The outlook provided by the company for 2010 is not very bright either. Aetna projects full-year 2010 operating EPS in the range of $2.55 − $2.65, way below the Zacks Consensus Estimate of $2.86. Consequently, we advise investors to avoid the stock.

In general, health insurers are facing a drop in enrollment in their commercial segment. Insurers like Aetna Inc., Cigna Corp. (CI) and Humana Inc. (HUM) have resorted to job cuts to tide over difficult times.

The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors.

In the present scenario, investor sentiment in healthcare continues to be driven by decisions in the Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in the Congress, healthcare policy changes remain an important indicator to investing in the sector. The Health Bill intends to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income.

President Obama has made a last-ditch effort to revive the stalled U.S. healthcare overhaul with a plan to make insurance more affordable and to bolster government authority to regulate premium hikes. The plan, which aims to break an impasse in the U.S. Congress, intends to provide coverage to millions of uninsured Americans and set up federal monitoring of private insurers' rate increases. The President’s proposal comes following months of debate on reform in the Senate and House of Representatives over their respective legislation.

As per the plan, health insurers would have to spend at least 80% of their premiums on medical care, a move that could result in penalties for 16% of health insurers. Furthermore, the proposed plan intends to penalize health insurers who spend more than 20% of premiums on operational costs, such as salaries and marketing.

Exorbitant rate hikes and profit margins became the subject of public debate after WellPoint Inc. (WLP) issued letters to the policyholders of its subsidiary Anthem Blue Cross in California, warning them of steep rate hikes.

Recently, the U.S. House of Representatives voted to strip health insurance companies of a 65-year-old antitrust exemption. The 406 to 19 vote aims to repeal an antitrust exemption that has meant that states take the lead in enforcing antitrust law for health insurers.

OPPORTUNITIES

We are positive on Health Net Inc. (HNT) on which we have an Outperform rating. While we remain concerned about the decline in membership, we believe a gradual improvement of the US economy should improve its membership status. Moreover, a strong balance sheet should enable it to tackle the current scenario.

Health technology holds the promise of improved operating efficiencies for many parts of the healthcare industry, hospitals included. However, in the short term those that stand to benefit the most from the stimulus are companies whose business models are based on information technology platforms.

One such company is BioScrip, Inc. (BIOS) on which we are positive despite its neutral rating. BioScrip is a specialty pharmacy services provider and pharmacy benefit manager. The company operates two interrelated business segments, namely: Specialty Services, which consists of specialty pharmacy distribution and clinical management services; and Traditional Pharmacy Services (previously referred to as PBM Services), which consists of pharmacy benefit management and traditional mail services.

The company’s diversified product mix across several key disease areas including immunology, multiple sclerosis and oncology should drive growth. The oral oncology business continues to show robust growth and should remain a strong part of the company’s business. We are pleased to see that the company is working on expanding its national reach and local presence and is adding infusion capacity in markets which have a large number of members.

We believe BioScrip is well-positioned to benefit from future healthcare reform initiatives like broader insurance coverage, the approval of a pathway for bio-similars and incentives supporting the utilization of information technology systems. The implementation of these initiatives is in line with the company’s strategy and should bode well for its future.

Another company on which we are positive -- despite its current Neutral recommendation -- is ZOLL Medical Corporation (ZOLL). We are pleased with the company’s wide range of products and significant international presence. The company has made multiple acquisitions in the past, which have aided growth and is looking out for more such opportunities.

The company is a leading player in the global market for external defibrillators, which is worth over $1 billion annually. ZOLL Medical has innovated a wide range of product features that have become the standard of care in the external defibrillator industry. The company is expanding its offerings to sustain growth.

WEAKNESSES

We recommend avoiding names like Molina Healthcare (MOH), on which we have an Underperform rating because of its declining profitability attributable to increasing medical costs due to the H1N1 influenza pandemic and costs associated with recently enrolled members. The impact of the pandemic is significant and has the potential to worsen in the coming quarters, affecting its profitability further.

Another company on which we are negative and have an Underperform rating is Aetna Inc. (AET), a diversified health care benefits company. Recently, the company delivered disappointing fourth quarter 2009 results. Aetna reported fourth quarter operating earnings per share (EPS) of 40 cents, missing the Zacks Consensus Estimate of 42 cents and was 58% lower than 96 cents reported in the year-ago quarter.

The primary reason for the decline was lower commercial underwriting margin, lower operating earnings in the Group Insurance business and an increase in pension expenses, partially offset by the lower number of outstanding shares. For full year 2009, operating EPS came in at $2.75, a 30% decline from last year.

The company is witnessing several headwinds such as rising unemployment, uncertainty related to healthcare reform and increasing cost pressure among others. Furthermore, intense competition facing the company is also a concern. Aetna competes with local and regional healthcare benefit plans in addition to large commercial health benefit insurance companies such as United Health (UNH) and WellPoint, among others, and Blue Cross/Blue Shield plans.

The outlook provided by the company for 2010 is not very bright either. Aetna projects full-year 2010 operating EPS in the range of $2.55 − $2.65, way below the Zacks Consensus Estimate of $2.86. Consequently, we advise investors to avoid the stock.

In general, health insurers are facing a drop in enrollment in their commercial segment. Insurers like Aetna Inc., Cigna Corp. (CI) and Humana Inc. (HUM) have resorted to job cuts to tide over difficult times.

The AMICAS acquisition is valued at $6.05 cash per share for an aggregate of $248 million. Merge has established an account with $40 million of pre-funded proceeds from its mezzanine investors. A portion of such pre-funded proceeds will be escrowed, which will be directly accessible by AMICAS, post-merger. AMICAS is a leader in image and information management solutions.

Merge’s bid is well ahead of Thoma Bravo LLC’s bid of $5.35 per share in cash. The company has already incurred several million dollars of non-refundable fees and expenses for this acquisition.

The successful acquisition of AMICAS will enable Merge to acquire one of its main competitors and widen its customer base. This will in turn expand the company’s top-line. Merge is a healthcare software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow, and intelligently managing and distributing diagnostic images and information throughout the healthcare enterprise.
 
Merge was paralyzed by several issues in the past like a dwindling cash balance, management turnover, accounting miscues and litigations. The real turnaround started from the second quarter of 2008 when the company received a much needed cash infusion of $20 million from Merrick RIS, LLC in May 2008.
Currently, we have an Underperform recommendation for Merge.

Molina's profit fell approximately 48.2% to $30.9 million in fiscal 2009 from 2008. The decline in profit was attributable to higher operating expenses. The increase in medical costs was attributable to the H1N1 influenza and costs associated with recently enrolled members.

We are also concerned about the intense competition facing Molina. We have an Underperform rating on the stock.Zacks Investment Research

Quarterly results

Total sales in the fourth quarter increased roughly 28% year over year to $19.3 million. Growth was led by strong Services and maintenance revenues that increased 62% year over year to $11.7 million. Software and other revenues declined 3% year over year to $7.6 million.

Merge registered a contraction in margins in the fourth quarter. Gross margin declined 370 basis points (bps) year over year to 65.9%. Operating margin declined 1,680 bps year over year to 7.6%.

Fiscal year results

Total sales in fiscal 2009 increased 18% year over year to $66.8 million. Growth was witnessed across all business segments. Services and maintenance revenues increased 16% year over year to $33.8 million. Software and other revenues increased 20% year over year to $33.0 million.

Merge ended fiscal 2009 with a cash balance of $19.6 million, a sequential increase of $2.7 million. Cash flow from operations declined by $5.4 million in the fourth quarter, mainly on account of $3.1 million of interest and early debt retirement costs.

Merge is a healthcare software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow, and intelligently managing and distributing diagnostic images and information throughout the healthcare enterprise.

Merge’s main competitors include AllScripts-Misys Healthcare Solutions (MDRX) and Amicas, Inc. (AMCS).

While 5 of the 23 analysts have lowered their earnings estimates for the next quarter (ending March 31, 2010) in the last 30 days, 4 have moved in the opposite direction. Furthermore, the magnitude of the revisions is negligible. As a result of the lack of strength and magnitude of the revisions our short-term recommendation on the stock is Hold.
 
We are Neutral on Quality Systems in the long-term as well. The stock is expected to perform in line with the overall U.S. equity market over the next 6-12 months.

Below we will share with you 5 top rated healthcare funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect the fund to outperform its peers in the future. To view the Zacks Rank and past performance of all healthcare funds, then click here.

Putnam Global Health Care A (PHSTX) invests the majority of its assets in health care companies worldwide. It focuses on large and mid-cap companies, but may also consider firms of smaller size. The healthcare fund returned 25.16% over the last one year period.

The Fund Manager is Kelsey Chen and she has managed this healthcare fund since 2005.

Fidelity Select Medical Delivery (FSHCX) seeks long-term capital growth by investing in firms engaged in the delivery of health care services, such as those which manage hospitals, nursing homes or similar organizations. It is non-diversified and may also purchase foreign securities. It is a no load fund.

The healthcare fund returned 49% in 2009 and has a ten year annualized return of 12.82%.

Delaware Healthcare A (DLHAX) invests at least 80% of its assets in both domestic and foreign health care companies across all market capitalizations. It is non diversified and may consider companies located in emerging markets. The healthcare fund returned 61.31% in 2009.

This healthcare fund has an expense ratio of 1.60% compared to a category average of 1.91%.

Schwab Health Care (SWHFX) seeks long term capital appreciation by investing primarily in domestic health care companies, but may also use up to 25% its assets to purchase stock in foreign firms. It may also consider futures contracts as an investment choice. This healthcare fund has a five year annualized return of 4.1%.

Larry M Mano is the fund manager and has managed this healthcare fund since 2000.

Rydex Biotechnology (RYOIX) invests a large share of its assets in equity securities and derivatives issued by domestic Biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 19.52% in 2009 has a three year annualized return of 4.15%.

As of December 2009, this healthcare fund held 29 issues, with 13.51% of its total assets invested in Amgen, Inc.

To view the Zacks Rank and past performance of all healthcare funds, then click here.

About Zacks Mutual Fund Rank

By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Learn more about the Zacks Mutual Fund Rank at http://www.zacks.com/funds/mutualfund/

We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles.

Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy.

Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed as part of the Stimulus Package initiatives to encourage hospitals and physicians to modernize their health record keeping. Names in this area include Allscripts-Misys Healthcare Solutions, Inc. (MDRX) and Omnicell Inc. (OMCL). However, neither of these companies have the above-mentioned attributes that differentiate them from the others. As such, we have a Neutral rating on these stocks.

We advise investors to avoid companies that have grown historically through acquisitions. These companies may find it difficult to fund acquisitions in the future. Also, they face increasing challenges in delivering operational synergies from these acquisitions, which are considered to be the prime reason for failures of Mergers & Acquisitions. Additionally, the financial statements of these companies have a large number of one-time items that affect the quality of earnings.

OPPORTUNITIES

In our portfolio, we see growth potential in companies dealing with cardiovascular devices and surgical equipment, Neuro, blood-related and disposable products. Names in this list include Medtronic, Inc. (MDT), Haemonetics Corporation (HAE), Intuitive Surgical, Inc. (ISRG), Boston Scientific Corporation (BSX), St. Jude Medical Inc. (STJ) and Becton, Dickinson and Company (BDX). These are all producers of life-sustaining products and are less affected by economic turbulence. Among these names, Medtronic has a diversified presence in Cardiovascular, Neuro, Spinal, Diabetes, ENT, etc.

The above-mentioned names are all leaders in their respective fields and are potential winners in the long run. Although Becton, Dickinson is the only Buy-rated stock according to the Zack Rank at this time, we will closely monitor their performances in the current quarter. They are all strong candidates for upgrades.

WEAKNESSES

We advise investors to avoid companies in the orthopedic domain until we see a complete economic recovery. Companies in this space have suffered from the economic downturn as patients deferred their elective procedures. Names on this list include Conmed Corporation (CNMD), Symmetry Medical, Inc. (SMA), Wright Medical Group, Inc. (WMGI) and Hanger Orthopedic Group Inc. (HGR).

With the economic recovery underway, all these names have already been upgraded to Neutral in the past few months. However, the economic indicators are pointing that the economy is not out of the woods yet. Hence, we recommend investors to avoid these companies until the second half of 2010 when we hope to see a complete recovery.

We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles.

Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy.

Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed as part of the Stimulus Package initiatives to encourage hospitals and physicians to modernize their health record keeping. Names in this area include Allscripts-Misys Healthcare Solutions, Inc. (MDRX) and Omnicell Inc. (OMCL). However, neither of these companies have the above-mentioned attributes that differentiate them from the others. As such, we have a Neutral rating on these stocks.

We advise investors to avoid companies that have grown historically through acquisitions. These companies may find it difficult to fund acquisitions in the future. Also, they face increasing challenges in delivering operational synergies from these acquisitions, which are considered to be the prime reason for failures of Mergers & Acquisitions. Additionally, the financial statements of these companies have a large number of one-time items that affect the quality of earnings.

OPPORTUNITIES

In our portfolio, we see growth potential in companies dealing with cardiovascular devices and surgical equipment, Neuro, blood-related and disposable products. Names in this list include Medtronic, Inc. (MDT), Haemonetics Corporation (HAE), Intuitive Surgical, Inc. (ISRG), Boston Scientific Corporation (BSX), St. Jude Medical Inc. (STJ) and Becton, Dickinson and Company (BDX). These are all producers of life-sustaining products and are less affected by economic turbulence. Among these names, Medtronic has a diversified presence in Cardiovascular, Neuro, Spinal, Diabetes, ENT, etc.

The above-mentioned names are all leaders in their respective fields and are potential winners in the long run. Although Becton, Dickinson is the only Buy-rated stock according to the Zack Rank at this time, we will closely monitor their performances in the current quarter. They are all strong candidates for upgrades.

WEAKNESSES

We advise investors to avoid companies in the orthopedic domain until we see a complete economic recovery. Companies in this space have suffered from the economic downturn as patients deferred their elective procedures. Names on this list include Conmed Corporation (CNMD), Symmetry Medical, Inc. (SMA), Wright Medical Group, Inc. (WMGI) and Hanger Orthopedic Group Inc. (HGR).

With the economic recovery underway, all these names have already been upgraded to Neutral in the past few months. However, the economic indicators are pointing that the economy is not out of the woods yet. Hence, we recommend investors to avoid these companies until the second half of 2010 when we hope to see a complete recovery.

We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles.

Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy.

Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed as part of the Stimulus Package initiatives to encourage hospitals and physicians to modernize their health record keeping. Names in this area include Allscripts-Misys Healthcare Solutions, Inc. (MDRX) and Omnicell Inc. (OMCL). However, neither of these companies have the above-mentioned attributes that differentiate them from the others. As such, we have a Neutral rating on these stocks.

We advise investors to avoid companies that have grown historically through acquisitions. These companies may find it difficult to fund acquisitions in the future. Also, they face increasing challenges in delivering operational synergies from these acquisitions, which are considered to be the prime reason for failures of Mergers & Acquisitions. Additionally, the financial statements of these companies have a large number of one-time items that affect the quality of earnings.

OPPORTUNITIES

In our portfolio, we see growth potential in companies dealing with cardiovascular devices and surgical equipment, Neuro, blood-related and disposable products. Names in this list include Medtronic, Inc. (MDT), Haemonetics Corporation (HAE), Intuitive Surgical, Inc. (ISRG), Boston Scientific Corporation (BSX), St. Jude Medical Inc. (STJ) and Becton, Dickinson and Company (BDX). These are all producers of life-sustaining products and are less affected by economic turbulence. Among these names, Medtronic has a diversified presence in Cardiovascular, Neuro, Spinal, Diabetes, ENT, etc.

The above-mentioned names are all leaders in their respective fields and are potential winners in the long run. Although Becton, Dickinson is the only Buy-rated stock according to the Zack Rank at this time, we will closely monitor their performances in the current quarter. They are all strong candidates for upgrades.

WEAKNESSES

We advise investors to avoid companies in the orthopedic domain until we see a complete economic recovery. Companies in this space have suffered from the economic downturn as patients deferred their elective procedures. Names on this list include Conmed Corporation (CNMD), Symmetry Medical, Inc. (SMA), Wright Medical Group, Inc. (WMGI) and Hanger Orthopedic Group Inc. (HGR).

With the economic recovery underway, all these names have already been upgraded to Neutral in the past few months. However, the economic indicators are pointing that the economy is not out of the woods yet. Hence, we recommend investors to avoid these companies until the second half of 2010 when we hope to see a complete recovery.

If Democrats fail to win the seat of late Senator Edward Kennedy, Republicans would have the necessary 41 votes to stall Democratic proposals, including the healthcare bill.  Those speculations made healthcare stocks look attractive yesterday.        

Technology shares rallied after a Credit Suisse (NYSE:CS) analyst raised his rating on Ciena Corp. (NASDAQ:CIEN), a maker of telecommunications equipment, saying revenue at the firm would beat expectations.

Health care stocks surged 2%, led by gains in DJIA components Merck (NYSE:MRK), up 2.9%, and Pfizer (NYSE:PFE), up 2.6%.  Health insurers also found favor with investors, with Humana (NYSE:HUM) rising 7.1%, Aetna (NYSE:AET) up 4.2%, and UnitedHealth Group (NYSE:UNH) up 4.1%.

On Tuesday, the Dow Jones industrial average rose 115.78 points, or 1.1%, to 10,725.43.  The broader Standard & Poor's 500 index rose 14.20 points, or 1.3%, to 1,150.23 points.  The technology-heavy Nasdaq composite index rose 32.41, or 1.4%, to 2,320.40.  It was the highest close for the Dow and the S&P 500 index in more than 15 months.  The market’s measure of volatility, the CBOE Vix, dropped 1.8% to 17.58.  Volume on the NYSE was a moderate 1.03 billion shares, with advancers ahead of losing issues by a 7-to-1 margin.

The dollar rose against a basket of currencies, up 0.7% to 77.51, as the euro continued to decline on Greece's debt issues.  As risk appetites grew, US Treasuries moved lower, with the 10-year down 6/32, and its yield moving higher to 3.700%. 

Of the thirty DJIA components, only four closed lower, with JP Morgan (NYSE:JPM) retreating 0.9% as the company said it sees larger-than-expected credit card write offs.  Kraft (NYSE:KFT) shares slipped 0.6% after the firm raised its bid for Cadbury (NYSE:CBY) to $19.6 billion, and the UK company approved the bid.  Boeing (NYSE:BA) shares fell 0.3%; this morning's news revealed its $10 billion in orders for 71 planes from recently-bankrupt Japan Airlines was more than previously disclosed.

All ten S&P500 sectors closed higher in yesterday's trade with healthcare shares leading the charge.  Gains were accorded to health care (+2.0%), basic materials (+1.8%), technology (+1.5%), telecommunications (+1.4%), utilities (+1.3%), financials (+1.2%), industrials (+1.1%), consumer services (+1.1%) oil and gas (+0.8%), and consumer goods (+0.7%).

Citigroup's (NYSE:C) results before the open failed upset investors’ calculations, as results of 33 cents were in line with Street estimates.  Citigroup noted a drop in consumer losses during the quarter with fewer write offs.

IBM (NYSE:IBM) came out with its numbers after the close.  The company reported fourth quarter results of $3.59 a share, ahead of consensus estimates of $3.47, and revenues of $27.2 billion exceeded estimates of $26.96 billion, helped by cost-cutting measures.  Also, its projections of 2010 earnings of at least $11.00 per share was ahead of Street projections of $10.88.

The poor preliminary results are attributable to significant costs associated with the H1N1 flu. Molina Healthcare intends to announce complete results for the fourth quarter as well as fiscal 2009 on Feb 11, 2010.

Molina Healthcare believes that premium revenues for the quarter will come in at $962 million, thus reflecting an approximate 18% year-over-year increase. Furthermore, revenues for fiscal 2009 are expected to be $3.7 billion, up approximately 19%.

The drastic fall in earnings expectations despite the rise in revenues is primarily attributable to increased expected medical costs. The H1N1 influenza and the costs associated with recently enrolled members were the key contributors to the higher medical costs. The impact of the H1N1 flu epidemic is significant and has the potential of getting worse in the coming quarters.

Furthermore, we remain concerned about the competition that Molina Healthcare is facing. Consequently, we have an Underperform rating on the stock.

Molina Healthcare, headquartered in Long Beach, California, is a multi-state managed care organization participating exclusively in government-sponsored health care programs catering to low-income persons, such as the Medicaid program and the Children’s Health Insurance Program (CHIP).

That gain is more than enough to make THC a top-performing Zacks #1 Rank stock today. Volume, too, has soared to more than 20 million shares, which is 3 times the average daily volume of about 6.8 million.

Tenet Healthcare, through subsidiaries and affiliates, owns and operates acute care hospitals, ambulatory surgery centers and diagnostic imaging centers. It is the only company from the Medical - Hospitals industry on today's Zacks #1 Rank List.

Earnings Estimates for Tenet Healthcare

The positive analyst news today probably won't make much of a difference to THC's earnings estimates - at least not as much as a strong quarterly report would. But expectations are sharply higher from 3 months ago, while staying rather tame since.

The Zacks Consensus Estimate for 2009 is at 15 cents per share, which is up a penny, or 7.1%, from 2 months ago. However, when you look back 3 months, that guidance has increased by 87.5%.

The Zacks Consensus Estimate for the current year has stayed unchanged at 21 cents per share over the past 2 months. But it too is up sharply in 3 months; gaining 61.5% in that time.

Third-Quarter Report

In what was a pretty good quarter for healthcare stocks in general, Tenet Healthcare announced third-quarter earnings per share of 3 cents in early November, excluding items. This result substantially beat the Zacks Consensus Estimate of a 2-cent loss by 250%.

Revenue advanced by almost 6% to $2.26 billion from $2.14 billion.

Reflecting the stronger-than-expected third-quarter results, Tenet Healthcare raised its outlook for 2009 adjusted EBITDA to between $925 million and $975 million, compared to its previous estimate of $900 million to $950 million.

Zacks Investment Research

The contract will allow the enrollees of Humana commercial health plans access to New West Physicians’ 13 office locations, 49 physicians and 12 nurse practitioners. The deal is applicable only to Humana commercial policy members. The benefits cannot be availed by Medicare Advantage members.

We believe that this move by the company will provide its commercial health plan members with increased access to healthcare related facilities which will enable them to monitor their health in a better manner. The new facilities for the members will encourage non-members to undertake Humana memberships. The increased membership will result in higher revenues, thus helping to sustain growth.

Humana, founded in 1964, provides health insurance benefits under Health Maintenance Organization (HMO), Private Fee- For-Service (PFFS) and Preferred Provider Organization (PPO) plans. Humana also provides other benefits with specialty products including dental, vision and other supplementary benefits.  The company is one of the largest health care plan providers in the United States, with approximately 10.3 million medical members and approximately 7.3 million specialty-benefit members. The company competes with other big players in the industry such as Aetna Inc. (AET), CIGNA Corp. (CI) and UnitedHealth Group, Inc. (UNH).

The mergers and acquisition front witnessed a busy Monday as Bucyrus International (NASDAQ:BUCY) offered to buy the mining operations of Terex Corp. (NYSE:TEX) in a $1.3 billion all-cash deal.  Giving healthcare issues a major lift was Sanofi-Aventis’ (NYSE:SNY) announcement to acquire retail health products maker Chattem (NASDAQ:CHTT) in a $1.9 billion deal. 

Premarket futures suggest a higher opening on the Wall Street, even as Moody's Investor Services (NYSE:MCO) became the third rating agency to downgrade Greece's government bonds.  Dow Jones industrial average futures rose 29, or 0.3 percent, to 10,371. Standard & Poor's 500 index futures rose 3.50, or 0.3 percent, to 1,111.70, while Nasdaq 100 index futures rose 8.00, or 0.4 percent, to 1,833.50.

Meanwhile, a number of analyst upgrades also helped the broader market yesterday.  Alcoa Inc. (NYSE:AA), which entered into a $10.8 billion deal with the Saudi Arabian Mining Co. to develop a major mining operation, jumped 7.9% after Morgan Stanley (NYSE:MS) lifted the stock to “overweight."  Morgan Stanley (NYSE:MS) said it sees a tight market for aluminum pricing “well into 2010."  The analyst increased the earnings estimate to 75 cents from 50 cents and the price target to $22.

Goldman Sachs (NYSE:GS) added to the upbeat sentiment as it recommended shares of Mosaic (NYSE:MOS), and added Potash (NYSE:POT) to its Conviction Buy List, on positive outlook for fertilizer prices. 

Barclays Capital (NYSE:BCS) upgraded shares of Intel (NASDAQ:INTC) to "overweight" from "market weight," basing its decision on "seemingly solid end market conditions, an upward bias to estimates and intriguing valuation." Intel shares advanced 2.3%.

On Monday, the Dow Jones industrial average advanced 85 points, or 0.8%, to 10,414.14.  The Dow average is now up 0.7% for December.  The S&P 500 index climbed 11 points, or 1.1%, to 1,114.05.  The Nasdaq composite advanced 26 points, or 1.2%, to 2,237.66, its highest level since September 2008.   Volume was down to a modest 1.013 billion shares, with advancing issues ahead of decliners by a five-to-one margin.  The dollar advanced 0.4% to 78.10 against a basket of currencies.

The difference between yields of the 2- and 10- year notes widened to a record divide as the yield on the 2-year rose 8 bps to 0.87%, while it rise 15 bps on the 10-year to 3.69%.

Healthcare stocks, which have been among the laggards this year, advanced 1.1% yesterday.  As the final revisions of the $871 billion reform package took shape and the bill appeared headed for a final, Thursday vote, investors viewed the sector with increased confidence.  Aetna (NYSE:AET) gained 4.7%, Cigna (NYSE:CI) advanced 3.9%, Humana (NYSE:HUM) rose 3.5%, and WellPoint (NYSE:WLP) closed up 2.9%.

Chicago, IL – December 18, 2009 – Zacks.com announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Healthcare Industry, including UnitedHealth Group Inc. (UNH), Cigna Corp. (CI), Pfizer Inc. (PFE), GlaxoSmithKline Plc (GSK) and Merck & Co Inc. (MRK).

Healthcare Stock Review – Dec. 2009

The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors.

In the present scenario, investor sentiment in healthcare continues to be driven by decisions in Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in Congress, healthcare policy changes remain an important indicator to investing in the sector.

Even though legislation -- which aims to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income -- was passed in the House of Representatives, it is facing opposition in the Senate mainly due to the government’s intention to compete with private insurers.

Under the legislation, practices such as denying coverage on the basis of pre-existing medical conditions would be discontinued and insurers would no longer be able to charge higher premiums on the basis of gender or medical history. Furthermore, the industry would no longer enjoy an exemption from federal antitrust restrictions on price gouging, bid rigging and market allocation. Health insurers such as UnitedHealth Group Inc. (UNH) and Cigna Corp. (CI) could face increased competition, more scrutiny and fewer protections under the bill.

The House version of the bill would not be profitable to drugmakers like Pfizer Inc. (PFE), GlaxoSmithKline Plc (GSK) and Merck & Co Inc. (MRK). They would be required to pay rebates to the government for drugs used by the elderly and disabled Medicare patients who also are on Medicaid.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5510.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5511.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Chicago, IL – December 4, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Humana Inc. (HUM), CVS Caremark (CVS), Aetna Inc. (AET), CIGNA Corp. (CI) and UnitedHealth Group, Inc. (UNH).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s Analyst Blog:

Good News for Humana Members

Recently, Humana Inc. (HUM) announced that it will collaborate with MinuteClinic, the retail health care division of CVS Caremark (CVS), which has been an in-network provider for Humana since 2006, on activities aimed at expanding access to convenient health care services for Humana-members. The agreement will result in increased focus on the management of routine illnesses, identifying and managing care related deficiencies, and making screenings available to identify risk factors resulting in chronic illnesses.

The agreement will see the Louisville-based Humana open a health clinic for its employees and dependents in downtown Louisville in 2010. It will be jointly operated by MinuteClinic and Humana’s subsidiary LifeSynch. Furthermore, the Humana-subsidiary will also join forces with MinuteClinic to provide Humana-members access to health screenings and illness management at about 500 MinuteClinic locations across the United States.

As per the agreement, the members of the health insurer will be encouraged to visit MinuteClinic locations for blood pressure testing, cholesterol screenings in addition to weight and body-mass index monitoring. Consequently, these members can take advantage of the existing health coaching services provided by LifeSynch in addition to the new facilities.

We believe that this move by Humana will provide its members, employees and their dependents with increased access to healthcare related facilities which will enable them to monitor their health in a better manner. The new facilities for the members should also encourage non-members to undertake Humana memberships. The increased membership will result in higher revenues, thus helping to sustain growth.

Humana Inc., founded in 1964, is one of the largest health care plan providers in the United States, with approximately 10.3 million medical members and approximately 7.3 million specialty-benefit members. The company competes with other big players in the industry such as Aetna Inc. (AET), CIGNA Corp. (CI) and UnitedHealth Group, Inc. (UNH).

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

The new platform can store digital images and associated patient information in a fully managed server environment, which are accessible at any time from any hosted network computer. Merge has provided a pay-per-study model which allows organizations access to these solutions and to the company’s other software, FusionWeb Clinician Access Portal and Fusion RIS 4.0 with Fusion Billing system.

The new product will help Merge to grow its top-line. Merge is a healthcare software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow, and intelligently managing and distributing diagnostic images and information throughout the healthcare enterprise.

Merge was paralyzed by several issues in the past like a dwindling cash balance, management turnover, accounting miscues and litigations. The real turnaround started from the second quarter of 2008 when the company received a much needed cash infusion of $20 million from Merrick RIS, LLC in May 2008.

Merge recently tapped the Chinese healthcare market when it formed an alliance with Shanghai Kingstar Winning Co., a leading healthcare IT provider in China. The alliance is likely to widen Merge's customer base and increase its top line. Congress' approval of more than $20 billion in spending on health information technology is also likely to benefit the company. However, a majority of the spending in the U.S. will be felt between 2011 and 2015. Its main competitors include AllScripts-Misys Healthcare Solutions (MDRX) and Amicas, Inc. (AMCS).

Company Description

DeVry is the holding company for DeVry University, Advanced Academics, Ross University, Chamberlain College of Nursing, Apollo College, Western Career College, Becker Professional Review and Fanor. The education provider prepares students for careers in technology, business and management, delivering undergraduate, graduate and life long learning programs.

Advanced Academics provides online secondary education to school districts throughout the U.S. Ross University offers programs for general medical and veterinary practice. Chamberlain College of Nursing delivers undergraduate health care education programs. Apollo College and Western Career College prepare students for careers in healthcare through certificate and associate degree programs.

Becker Professional Review prepares students for professional certification exams such as the certified public accountant (CPA), certified management accountant (CMA) and chartered financial analyst (CFA).

Based in Brazil, Fanor offers degree programs in business management, law and engineering through its four schools: Faculdades Nordeste, Faculdade Ruy Barbosa, Faculdade FTE and ÁREA1.

Rewarding Shareholders

The company recently boosted its dividend by 25% to 20 cents per share annually. The company pays dividends on a semi-annual basis, issuing the next 10-cent dividend on January 7 to shareholders of record as of December 11.

Record Results

The company announced a record fiscal first quarter. Earnings per share of 76 cents topped last year's 48 cents and exceeded the Zacks Consensus Estimate by 17%.

Revenues hit a record $431 million, representing a year-over-year increase of 42%.

"Our financial results this quarter were driven largely by exceptional revenue growth," said Daniel Hamburger, DeVry's president and chief executive officer. "Our institutions continue to experience strong enrollment and student retention, as evidenced by our results at Keller, Ross and Fanor. These financial results provide the resources for us to continue to make investments that enhance academic quality, improve student services, and expand access to education."

Bullish Forecasts

Analysts polled by Zacks are bullish on earnings forecasts for the fiscal year ending June 2010. Current projections of $3.19 per share are up from $3.01 over the past 60 days. For the following year, earnings expectations of $3.87 were increased from $3.63 over the same time period.

Alex Kolb is the Growth & Income Stock Strategist for Zacks.com. He also writes the popular daily commentary column for the ZacksElite.com service.Zacks Investment Research

Merge Healthcare recently tapped the Chinese healthcare market when it formed an alliance with Shanghai Kingstar Winning Co., a leading healthcare IT provider in China. The alliance is likely to widen Merge's customer base and increase its top line. Congress' approval of more than $20 billion in spending on health information technology is also likely to benefit the company. However, a majority of the spending in the U.S. will be felt between 2011 and 2015. Merge’s main competitors include AllScripts-Misys Healthcare Solutions (MDRX) and Amicas, Inc. (AMCS).